Company Overview
About General Proximity
General Proximity is a Cambridge, Massachusetts-based biotechnology company — backed by Y Combinator (W20) with $16 million in Series A funding in January 2025 led by Tomales Bay Capital — pioneering induced proximity medicines that work by bringing together disease-causing proteins to trigger their degradation or modulation, representing a next-generation therapeutic modality beyond traditional small molecule inhibitors and biologics. Founded in 2020, General Proximity combines computational chemistry, medicinal chemistry, and structural biology to design molecular glues and PROTACs (proteolysis-targeting chimeras) for previously undruggable targets in oncology and other disease areas — targeting the protein degradation mechanisms that cells use naturally to eliminate aberrant proteins.
Business Model & Competitive Advantage
General Proximity's induced proximity platform addresses the fundamental limitation of conventional drug design: traditional small molecule drugs work by occupying the active site of a disease-relevant protein to block its function (enzyme inhibition, receptor antagonism) — but this approach only works for 10-15% of disease-relevant proteins that have accessible binding pockets. The remaining 85%+ are 'undruggable' by conventional methods. Induced proximity medicines (molecular glues and PROTACs) work differently — rather than blocking a protein, they recruit the cell's own protein degradation machinery (the ubiquitin-proteasome system) to tag and eliminate the disease-causing protein entirely. This catalytic mechanism (one drug molecule can degrade multiple copies of the target protein) enables sub-nanomolar efficacy at low drug doses, and the protein elimination approach provides durable target engagement that inhibition-based drugs cannot achieve. General Proximity's computational platform accelerates the design of these ternary complex-forming molecules by predicting which molecular configurations will successfully recruit the degradation machinery to the target protein.
Competitive Landscape 2025–2026
In 2025, General Proximity competes in the induced proximity, molecular glue, and protein degradation drug discovery market with C4 Therapeutics (NASDAQ: CCCC, PROTAC-based oncology, $600M raised), Arvinas (NASDAQ: ARVN, PROTAC platform, $1B+ raised), and Kymera Therapeutics (NASDAQ: KYMR, protein degradation, $700M+ raised) for precision oncology and targeted protein degradation drug development platform adoption. Tomales Bay Capital's Series A leadership reflects biotech venture conviction in the induced proximity modality. Y Combinator W20 backing (unusual for a biotech company in YC) connects General Proximity with the computational biology and AI drug discovery investment community. The 2025 strategy focuses on advancing the lead oncology programs toward IND-enabling studies, building the AI-assisted ternary complex structure prediction for accelerated molecular glue design, and expanding the disease area pipeline beyond oncology to targeted protein degradation in neurodegeneration and inflammatory diseases.
Recent Activity
View all →Key Differentiators
Emerging Innovator
General Proximity is an emerging player bringing innovative solutions to the Healthcare market.
Frequently Asked Questions
Estimated Visibility Trend (Beta)
Simulated 8-week rolling score
Based on estimated brand signals. Historical tracking coming soon.
Similar Brands
Browser Use
Browser Use is an open-source project that provides a Python library allowing AI agents and large language models to control web browsers as a tool. The library sits between LLM APIs and browser autom
athenahealth
athenahealth is a cloud-based electronic health records (EHR), medical billing, and practice management company founded in 1997 and headquartered in Watertown, Massachusetts. The company was built on
Veeva Systems
Veeva Systems Inc. is the leading cloud software provider for the global life sciences industry, headquartered in Pleasanton, California. Founded in 2007 by Peter Gassner (a former Salesforce executiv
Oracle Health
Oracle Health is the healthcare technology business unit of Oracle Corporation (NYSE: ORCL) — providing electronic health records (EHR), clinical workflow management, health information exchange, reve
Idexx Laboratories
IDEXX Laboratories is the global leader in veterinary diagnostics and information technology for companion animal healthcare, founded in 1983 by David Shaw in Westbrook, Maine, where it remains headqu
Revvity
Revvity, Inc. (formerly PerkinElmer) is a global life science tools and diagnostics company, rebranded in 2023 to signal its transformation from a diversified instruments company into a focused provid
Compare General Proximity with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from General Proximity? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim General Proximity Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention General Proximity vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →